AbCellera Biologics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.02.22	Erste Schätzungen: AbCellera Biologics legt Quartalsergebnis vor (finanzen.net)
27.01.22	AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 (Businesswire)
07.12.21	AbCellera Announces Changes to Its Board of Directors (Businesswire)
03.12.21	AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12 (Businesswire)
02.12.21	AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer (Businesswire)
08.11.21	Ausblick: AbCellera Biologics zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
17.09.21	Pre-market Movers: CRVS, ABCL, BGNE, IPHA, IRNT… (RTTNews)
23.06.21	Pre-market Movers: ACST, TENX, GMTX, EYES… (RTTNews)
22.06.21	AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada (Businesswire)
10.06.21	AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares (Businesswire)
13.05.21	AbCellera Reports Q1 2021 Business Results (Businesswire)
11.05.21	AbCellera to Present Virtually at Berenberg Conference on May 18, 2021 (Businesswire)
06.05.21	AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy (Businesswire)
04.05.21	New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials (Businesswire)
29.04.21	AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals (Businesswire)
21.04.21	AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021 (Businesswire)
14.04.21	AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration (Businesswire)
05.04.21	Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19 (Businesswire)
10.03.21	AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19 (Businesswire)
05.03.21	EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients (Businesswire)
17.02.21	AbCellera to Present at the SVB Leerink Global Healthcare Conference (Businesswire)
11.02.21	AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer (Businesswire)
10.02.21	AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 (Businesswire)
03.02.21	AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call (Businesswire)
27.01.21	AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 (Businesswire)
26.01.21	AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% (Businesswire)
19.01.21	AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology (Businesswire)
21.12.20	AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico (Businesswire)
11.12.20	MÄRKTE USA/Wall Street von Unsicherheiten belastet (Dow Jones)
11.12.20	MÄRKTE USA/Unsicherheiten drücken Börsen ins Minus (Dow Jones)
11.12.20	MÄRKTE USA/Politische Risiken bremsen Wall Street (Dow Jones)
11.12.20	MÄRKTE USA/Politische Risiken dürften Wall Street drücken (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu AbCellera Biologics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten